Sandy Gould, Ph.D.

Sandy Gould is the senior director of drug discovery for the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. Her team consists of experienced drug discovery scientists whose mission is to collaborate closely with Broad scientists to translate their deep biological insights discovered into potential new therapeutics for a variety of diseases.

Gould spent 23 years at Takeda Pharmaceuticals (formerly Millennium Pharmaceuticals, Inc.), where she played a variety of roles including associate director of oncology and medicinal chemistry and director of scientific affairs in research strategy and operations within the oncology division. At Takeda, Gould managed academic collaborations, a group responsible for the creation and review of non-clinical pharmacology reports for agency filings, and multiple chemistry project teams. She contributed to several oncology and immuno-oncology projects, developed and managed intellectual property strategy across the company’s Cambridge-based chemistry department, and led an industry/NGO/academic collaboration focused on identifying and developing anti-malaria drugs with novel mechanisms of action. Just prior to joining the Broad, Gould was a senior director of project management at NextRNA Therapeutics, where she managed two drug discovery projects and coordinated collaborations with biology, biochemistry, and chemistry contract research organizations, as well as academic experts and small biotechnology companies, to support research progress. 

Gould, whose legal name is Alexandra, earned a B.A. from the University of Pennsylvania and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology. She completed postdoctoral training at Harvard University.